In the more than 30 years since the human epidermal growth factor receptor 2 (HER2) gene was first successfully explored, HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies.1
The FDA has approved several methods of assessing whether the gene is promoting tumor growth, and HER2 gene amplification and/or protein overexpression has been variously estimated to be at work in 10% to 34% of invasive breast cancers, with the frequency associated with tumor grade and carcinoma status.1-3
Established agents have proved effective in inhibiting HER2-positive forms of the disease, and now the treatment of such cancers is poised to enter a new era as strategies for dual inhibitors have emerged.
Edith A. Perez, MD
“This should prompt a renovated willingness to try and unveil peculiar aspects of HER2-positive breast cancer that have been apparently overlooked or misinterpreted until now,” he said.